Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later

Ehinger, Anna LU orcid ; Remse, Inger LU ; Lövgren, Kristina LU ; Hegardt, Cecilia LU ; Häkkinen, Jari LU orcid ; Saal, Lao LU orcid ; Vallon-Christersson, Johan LU orcid and Borg, Åke LU (2017) 29th European Congress of Pathology In Virchows Archiv 471(Supplement 1). p.299-299
Abstract
Objective: To assessmyoepithelium with p63 in fresh breast cancer (BC)
tissue samples collected in RNA later for further analysis with Next
Generation Sequencing (NGS) technique. For a better understanding of
the NGS bulk-analysis, a central part of the sample in RNA-later is
formalin-fixed paraffin-embedded to score relative cellularity in % on
hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,
benign epithelium, lymphocytes and fat). Our aim is hence to test p63
immunohistochemistry (IHC) to highlight myoepithelium and to facilitate
the evaluation of the relative cellularity on BC-tissue pre-treated with
RNA-later.
Method: Two-hundred and twenty-four selected samples of fresh... (More)
Objective: To assessmyoepithelium with p63 in fresh breast cancer (BC)
tissue samples collected in RNA later for further analysis with Next
Generation Sequencing (NGS) technique. For a better understanding of
the NGS bulk-analysis, a central part of the sample in RNA-later is
formalin-fixed paraffin-embedded to score relative cellularity in % on
hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,
benign epithelium, lymphocytes and fat). Our aim is hence to test p63
immunohistochemistry (IHC) to highlight myoepithelium and to facilitate
the evaluation of the relative cellularity on BC-tissue pre-treated with
RNA-later.
Method: Two-hundred and twenty-four selected samples of fresh BC
tissue collected in RNA-later. A 10 mg central piece from each sample
was FFPE and assembled in a tissue-microarray (TMA) and sectioned to
HE and p63 IHC.
Results: All samples (n = 224) had internal control for myoepithelium
surrounding in situ cancer or benign epithelium. p63 showed positive
nuclear staining in myoepithelial cells in 92 % (206/224) of samples
and false negative p63 staining in 8 % (18/224).
Conclusion: p63 IHC is assessable in samples of FFPE BC-tissue pretreated
with RNA-later. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Virchows Archiv
volume
471
issue
Supplement 1
article number
E-PS-02-027
pages
1 pages
publisher
Springer
conference name
29th European Congress of Pathology
conference location
Amsterdam, Netherlands
conference dates
2017-09-02
external identifiers
  • pmid:28831497
ISSN
1432-2307
DOI
10.1007/s00428-017-2205-0
project
Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
language
English
LU publication?
yes
id
1332dc59-6252-4a6f-9df3-c6e6b7cdceb2
date added to LUP
2017-09-02 07:47:38
date last changed
2021-03-23 22:51:29
@misc{1332dc59-6252-4a6f-9df3-c6e6b7cdceb2,
  abstract     = {{Objective: To assessmyoepithelium with p63 in fresh breast cancer (BC)<br/>tissue samples collected in RNA later for further analysis with Next<br/>Generation Sequencing (NGS) technique. For a better understanding of<br/>the NGS bulk-analysis, a central part of the sample in RNA-later is<br/>formalin-fixed paraffin-embedded to score relative cellularity in % on<br/>hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,<br/>benign epithelium, lymphocytes and fat). Our aim is hence to test p63<br/>immunohistochemistry (IHC) to highlight myoepithelium and to facilitate<br/>the evaluation of the relative cellularity on BC-tissue pre-treated with<br/>RNA-later.<br/>Method: Two-hundred and twenty-four selected samples of fresh BC<br/>tissue collected in RNA-later. A 10 mg central piece from each sample<br/>was FFPE and assembled in a tissue-microarray (TMA) and sectioned to<br/>HE and p63 IHC.<br/>Results: All samples (n = 224) had internal control for myoepithelium<br/>surrounding in situ cancer or benign epithelium. p63 showed positive<br/>nuclear staining in myoepithelial cells in 92 % (206/224) of samples<br/>and false negative p63 staining in 8 % (18/224).<br/>Conclusion: p63 IHC is assessable in samples of FFPE BC-tissue pretreated<br/>with RNA-later.}},
  author       = {{Ehinger, Anna and Remse, Inger and Lövgren, Kristina and Hegardt, Cecilia and Häkkinen, Jari and Saal, Lao and Vallon-Christersson, Johan and Borg, Åke}},
  issn         = {{1432-2307}},
  language     = {{eng}},
  month        = {{09}},
  note         = {{Conference Abstract}},
  number       = {{Supplement 1}},
  pages        = {{299--299}},
  publisher    = {{Springer}},
  series       = {{Virchows Archiv}},
  title        = {{Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later}},
  url          = {{https://lup.lub.lu.se/search/files/30491346/ECP_2017_Asbtracts_Supplement_Final.pdf}},
  doi          = {{10.1007/s00428-017-2205-0}},
  volume       = {{471}},
  year         = {{2017}},
}